# Study to Investigate Dose Proportionality of the Fixed Dose Combination of COREG CR and Lisinopril.

> **NCT00549510** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 29 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** COREG CR and lisinopril (FDC)

## Key facts

- **NCT ID:** NCT00549510
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2010-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00549510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00549510, "Study to Investigate Dose Proportionality of the Fixed Dose Combination of COREG CR and Lisinopril.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00549510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*